SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)

 

Arvinas, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

04335A105

(CUSIP Number)

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

¨Rule 13d-1(c)

 

xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP NO. 04335A10513 GPage 2 of 10

 

1 NAMES OF REPORTING PERSONS
Nextech V Oncology, S.C.S., SICAV-SIF
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)
(a)     ¨       (b)     x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
5 SOLE VOTING POWER
1,694,351
6 SHARED VOTING POWER
0
7

SOLE DISPOSITIVE POWER

1,694,351

8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
1,694,351
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.3% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

 

(1)This Schedule 13G is filed by Nextech V Oncology, S.C.S., SICAV-SIF (“Nextech V LP”), Nextech V GP S.à r.l. (“Nextech V GP”), Dalia Bleyer (“Bleyer ”), James Pledger (“Pledger”) and Thomas Lips (“Lips” and together with Nextech V LP, Nextech V GP, Bleyer and Pledger, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)This percentage is based on 38,975,725 shares outstanding as of November 12, 2019, as reported in the Issuer’s final prospectus dated November 7, 2019 as filed with the Securities and Exchange Commission on November 12, 2019 (including the exercise in full of the underwriter’s option to purchase additional shares in such offering, as reported in the Issuer’s Current Report on Form 8-K, filed on November 12, 2019.

 

 

 

CUSIP NO. 04335A10513 GPage 3 of 10

 

1 NAMES OF REPORTING PERSONS
Nextech V GP S.à r.l.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)
(a)     ¨       (b)     x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH
5 SOLE VOTING POWER
1,694,351
6 SHARED VOTING POWER
0
7

SOLE DISPOSITIVE POWER 

1,694,351

8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
1,694,351
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.3% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)This percentage is based on 38,975,725 shares outstanding as of November 12, 2019, as reported in the Issuer’s final prospectus dated November 7, 2019 as filed with the Securities and Exchange Commission on November 12, 2019 (including the exercise in full of the underwriter’s option to purchase additional shares in such offering, as reported in the Issuer’s Current Report on Form 8-K, filed on November 12, 2019.

 

 

 

CUSIP NO. 04335A10513 GPage 4 of 10

  

1 NAMES OF REPORTING PERSONS
Dalia Bleyer
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)
(a)     ¨       (b)     x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Lithuania

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH
5 SOLE VOTING POWER
0
6 SHARED VOTING POWER
1,694,351
7

SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER
1,694,351

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
1,694,351
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.3% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)This percentage is based on 38,975,725 shares outstanding as of November 12, 2019, as reported in the Issuer’s final prospectus dated November 7, 2019 as filed with the Securities and Exchange Commission on November 12, 2019 (including the exercise in full of the underwriter’s option to purchase additional shares in such offering, as reported in the Issuer’s Current Report on Form 8-K, filed on November 12, 2019.

 

 

 

CUSIP NO. 04335A10513 GPage 5 of 10

  

1 NAMES OF REPORTING PERSONS
James Pledger
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(SEE INSTRUCTIONS)

(a)     ¨       (b)     x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
5 SOLE VOTING POWER
0
6 SHARED VOTING POWER
1,694,351
7

SOLE DISPOSITIVE POWER 

0

8 SHARED DISPOSITIVE POWER
1,694,351

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
1,694,351
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.3% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)This percentage is based on 38,975,725 shares outstanding as of November 12, 2019, as reported in the Issuer’s final prospectus dated November 7, 2019 as filed with the Securities and Exchange Commission on November 12, 2019 (including the exercise in full of the underwriter’s option to purchase additional shares in such offering, as reported in the Issuer’s Current Report on Form 8-K, filed on November 12, 2019.

 

 

 

CUSIP NO. 04335A10513 GPage 6 of 10

  

1 NAMES OF REPORTING PERSONS
Thomas Lips
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(SEE INSTRUCTIONS)

(a)     ¨       (b)     x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
5 SOLE VOTING POWER
0
6 SHARED VOTING POWER
1,694,351
7

SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER
1,694,351

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
1,694,351
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.3% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)This percentage is based on 38,975,725 shares outstanding as of November 12, 2019, as reported in the Issuer’s final prospectus dated November 7, 2019 as filed with the Securities and Exchange Commission on November 12, 2019 (including the exercise in full of the underwriter’s option to purchase additional shares in such offering, as reported in the Issuer’s Current Report on Form 8-K, filed on November 12, 2019.

 

 

 

CUSIP NO. 04335A10513 GPage 7 of 10

 

Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”) of Arvinas, Inc. (the “Issuer”).

 

Item 1(a) Name of Issuer:
   
  Arvinas, Inc.
   
Item 1(b) Address of Issuer’s principal executive offices:
   

5 Science Park

395 Winchester Avenue

New Haven, Connecticut 06511

   
Items 2(a) Name of Reporting Persons filing:

 

Nextech V Oncology, S.C.S., SICAV-SIF (“Nextech V LP”)

Nextech V GP S.à r.l. (“Nextech V GP”)

Dalia Bleyer  (“Bleyer ”)

James Pledger (“Pledger”)

Thomas Lips (“Lips”)

 

Item 2(b)Address or principal business office or, if none, residence:

 

  The address of the principal business office:

8 rue Lou Hemmer

L-1748 Senningerberg

Grand-Duché de Luxembourg

  

Item 2(c)Citizenship:

 

Name Citizenship or Place of Organization
Nextech V LP Luxembourg
Nextech V GP Luxembourg
Bleyer Lithuania
Pledger United Kingdom
Lips Switzerland

 

Item 2(d)Title of class of securities:

Common Stock, $0.001 par value per share

 

Item 2(e)CUSIP No.:

04335A105

 

Item 3If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:
  
 Not applicable.

  

Item 4Ownership
  
 The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2019.

 

 

 

CUSIP NO. 04335A10513 GPage 8 of 10

 

Reporting Persons Shares of
Common
Stock Held
Directly
Sole
Voting
Power
Shared
Voting
Power (1)
Sole
Dispositive
Power
Shared
Dispositive
Power (1)
Beneficial
Ownership
Percentage
of Class
(1)(3)
Nextech V LP 1,694,351 1,694,351 0 1,694,351 0 1,694,351 4.3%
Nextech V GP (2) 0 1,694,351 0 1,694,351 0 1,694,351 4.3%
Bleyer  (2) 0 0 1,694,351 0 1,694,351 1,694,351 4.3%
Pledger (2) 0 0 1,694,351 0 1,694,351 1,694,351 4.3%
Lips (2) 0 0 1,694,351 0 1,694,351 1,694,351 4.3%

 

  (1) Consists of 1,694,351 shares of Common Stock of the Issuer held directly by Nextech V LP.
  (2) The shares are held by Nextech V LP. Nextech V GP serves as the sole general partner of Nextech V LP and has sole voting and investment control over the shares owned by Nextech V LP and may be deemed to own beneficially the shares held by Nextech V LP. Nextech V GP owns no securities of the Issuer directly. Bleyer , Pledger and Lips are members of the board of managers of Nextech V GP and share voting and dispositive power over the shares held by Nextech V LP, and may be deemed to own beneficially the shares held by Nextech V LP. The managing members own no securities of the Issuer directly.
  (3) The 1,694,351 shares of Common Stock beneficially owned by the Reporting Person represent 4.3% of the Issuer’s outstanding Common Stock. This percentage is based on 38,975,725 shares outstanding as of November 12, 2019, as reported in the Issuer’s final prospectus dated November 7, 2019 as filed with the Securities and Exchange Commission on November 12, 2019 (including the exercise in full of the underwriter’s option to purchase additional shares in such offering, as reported in the Issuer’s Current Report on Form 8-K, filed on November 12, 2019.

 

Item 5Ownership of Five Percent or Less of a Class
  
 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

Item 6Ownership of More than Five Percent on Behalf of Another Person
  
 

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

 

Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

 

Item 8Identification and Classification of Members of the Group
  
 

Not applicable.

 

Item 9Notice of Dissolution of Group
  
 

Not applicable.

 

Item 10Certifications
  
 

Not applicable.

 

 

 

CUSIP NO. 04335A10513 GPage 9 of 10

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in the attached statement on Schedule 13G is true, complete and correct.

 

Dated: February 13, 2020

 

Nextech V Oncology, S.C.S., SICAV-SIF

 

By: Nextech V GP S.à r.l.
Its: General Partner

 

By: /s/ Dalia Bleyer  
  Dalia Bleyer , Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

Nextech V GP S.à r.l.  
     
By: /s/ Dalia Bleyer  
  Dalia Bleyer , Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

/s/ Dalia Bleyer  
Dalia Bleyer  
   
/s/ James Pledger  
James Pledger  
   
/s/ Thomas Lips  
Thomas Lips  

 

 

 

CUSIP NO. 04335A10513 GPage 10 of 10

  

Exhibit(s):

 

Exhibit 99.1: Joint Filing Statement

 

 

 

 

Exhibit 99.1

 

 

JOINT FILING STATEMENT

 

We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of Arvinas, Inc. is filed on behalf of each of us.

 

Dated: February 13, 2020

 

Nextech V Oncology, S.C.S., SICAV-SIF

 

By: Nextech V GP S.à r.l.
Its: General Partner

 

By: /s/ Dalia Bleyer  
  Dalia Bleyer , Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

Nextech V GP S.à r.l.  
     
By: /s/ Dalia Bleyer  
  Dalia Bleyer , Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

/s/ Dalia Bleyer  
Dalia Bleyer  
   
/s/ James Pledger  
James Pledger  
   
/s/ Thomas Lips  
Thomas Lips